Amylyx Pharmaceuticals (AMLX) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 103.3% versus a loss of 14.3%. Viking Therapeutics is the larger company by market cap ($3.53 billion vs $3.41 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | VKTX |
|---|---|---|
| Share price | $27.20 | $27.73 |
| Market cap | $3.41B | $3.53B |
| 1-day change | -0.84% | -2.84% |
| YTD return | +127.07% | -21.18% |
| 1-year return | +103.34% | -14.33% |
| 5-year return | — | +361.40% |
| EPS (TTM) | $-1.41 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $0 |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-144.74M | $-359.64M |
| 52-week high | $41.14 | $43.15 |
| 52-week low | $10.83 | $25.77 |
| Distance from 52-week high | -33.88% | -35.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +55.74% | +241.54% |
| Average volume | 2.35M | 4.13M |
| Shares outstanding | 125.51M | 127.17M |
| Employees | 136 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed VKTX by 117.7 percentage points over the past year.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
AMLX vs VKTX FAQ
Which is bigger, Amylyx Pharmaceuticals or Viking Therapeutics?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.53B compared with $3.41B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or VKTX?
AMLX returned +103.34% over the past 12 months, compared with -14.33% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.